Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA-MedSci.cn

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Ramalingam, S; Reungwetwattana, T; Chewaskulyong, B; Dechaphunkul, A; Lee, KH; Imamura, F; Nogami, N; Ohe, Y; Cheng, Y; Cho, BC; Cho, EK; Vansteenkiste, JF; Voon, PJ; Zhou, C; Gray, J; Hodge, R; Rukazenkov, Y; Soria, JC

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务